Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Thursday, April 21, 2011 - 12:01
in Health & Medicine
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.